Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed

  • Technology appraisal guidance
  • TA375
  • Published: 

Review decision – September 2019

Decision to conduct a partial review of TA375 for patients with moderate disease only

NICE had proposed that a partial review of TA375 for patients with moderate disease only should be planned into the appraisal work programme.

After consideration of all of the comments received during the review consultation, NICE’s Guidance Executive has decided to proceed with this proposal.

As the part review of TA375 will commence post 1 April 2019, this review will be subject to the charging mechanism for technology appraisals.

If a company does not participate in the assessment through non-payment or other reasons, their technology will not be assessed and therefore will not receive a recommendation within the final guidance.

Review proposal paper

Stakeholder list

This page was last updated: